Chinese Biological Company WuXi Biologics and Immunotherapy Company BioNTech in Germany Reach Research Service Agreement for Two Monoclonal Antibodies

January 11, 2024

Chinese biological company WuXi Biologics announced that its Biological Drug Research and Development Services (R-Research Services in CRDMO) has reached a research services agreement with immunotherapy company BioNTech in Germany. According to the agreement, WuXi Biologics will develop antibodies against two undisclosed targets for BioNTech through its patented technology platform (R-Research Services in CRDMO) for the development of a new generation of drug candidates. WuXi Biologics will receive an upfront payment of US$20 million and is eligible to receive research, development, registration, and commercialization milestone payments as well as tiered sales royalties.

from：Financial AI Telegram